Boston Scientific anticipates a difficult 2027 due to pricing policy in China and weakness
Article excerpt
(Automatic translation by Reuters using machine learning and generative AI, please refer to the following disclaimer: https://bit.ly/rtrsauto) by Padmanabhan Ananthan Boston Scientific BSX.N on Wednesday lowered its full-year profit forecast and warned that revenue and profit growth could prove difficult in 2027, citing pricing pressures in China and weakness in its core cardiac device business. The company's shares fell 5.3% in late afternoon trading. “We anticipate continued top-line pressure extending through 2027, which we believe will make it challenging to grow revenue and adjusted earnings per share,” said Chief Financial Officer Jon Monson on a conference call. The medical technology company now expects an adjusted profit for 2026 of between $3.16 and $3.18, compared to a previous range of $3.28 to $3.32. According to data compiled by LSEG, analysts are expecting an average profit of $3.23 per share. The company expects a fourth-quarter revenue decline of approximately 3% to 1% year-over-year, as well as an adjusted profit between 77 cents and 79 cents per share, which is below the analysts' estimate of 83 cents per share. Chief Executive Officer Mike Mahoney said: “There will be additional pricing headwinds in China in 2027, and growth is likely not going to be sufficient to offset the pressure from electrophysiology and Watchman next year.” Farapulse and Watchman...
Keep reading with a free account
The rest of this article, and every signal for Boston Scientific, is in your free account.
Extracted from this sentence
Boston Scientific now expects to finalize the acquisition of Penumbra, valued at $14.5 billion, in the first quarter of 2027, later than initially planned due to longer regulatory review procedures.
